<DOC>
	<DOC>NCT02530697</DOC>
	<brief_summary>Mucocutaneous leishmaniasis is endemic in the central region of Brazil and other countries worldwide. The standard treatment with meglumine antimoniate has a high rate of important adverse effects. This interventional study consists in a randomized clinical trial to access efficacy and safety of the association of miltefosine and pentoxifylline compared to meglumine antimoniate and pentoxifyline.</brief_summary>
	<brief_title>The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis, Mucocutaneous</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Mucosal leishmaniasis, not treated or at least 6 months without any treatment to leishmaniasis; Ages between 18 and 80 years old; Fertile female patients should use at least two contraceptive methods (hormonal and barrier); Agree to participate in the study and sign the informed consent term. Use of any leishmanicidal drugs six months prior; Clinical or laboratorial evidences of electrocardiographic disorders; Renal, hepatic, cardiac diseases, uncontrolled diabetes or AIDS; Hypersensitivity to meglucamine antimoniate; Pregnancy or lactation; Fertile females that do not agree to use contraceptive methods; Patients that do not agree to the informed consent term.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Mucocutaneous</keyword>
	<keyword>Miltefosine</keyword>
	<keyword>Pentoxifylline</keyword>
</DOC>